Excessive neutrophil recruitment is a common characteristic of patients with fatal lung failure, and attenuating neutrophilic responses by ADAM8 inhibition in combination with standard antibiotic strategies may provide beneficial effects for a wide spectrum of patients with ARDS, but future studies will need to determine if susceptibility to secondary infection increases following the treatment. This evidence concerns the gene ADAM8 and infection.